Physician profile
Stan T Lin
NPI 1538374368
$907.95
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $25.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $207.79 | 2019 | |
| Ucb, INC. | $195.62 | 2019-2020 | |
| Amgen INC. | $190.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.23 | 2019 | |
| Acadia Pharmaceuticals INC | $46.46 | 2019 | |
| Genzyme Corporation | $45.79 | 2019 | |
| Lilly USA, LLC | $33.89 | 2019 | |
| Neuropace, INC. | $25.66 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.32 | 2019 | |
| Adamas Pharmaceuticals, INC. | $21.13 | 2019 | |
| Biogen, INC. | $21.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.42 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.66 | 2020 | |
| Mdd US Operations, LLC | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stan Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.